Heparin-induced thrombocytopenia (HIT) is an autoimmune thrombotic disorder caused by antibodies to complexes between platelet factor 4 (PF4) released from activated platelets and heparin or cellular glycosaminoglycans (GAGs). Remarkably, anti-PF4/heparin antibodies develop in most patients exposed to heparin in settings characterized by intense platelet activation and inflammation such as coronary bypass surgery, yet only ~1% of patients develop HIT. The reason why only a subset of anti-PF4/heparin antibodies is associated with HIT is unclear and is only partially explained by IgG isotype and titer. Antibody binding and procoagulant activity develops over a narrow range of PF4/heparin (PF4/H) concentrations that foster formation of stable ultralarge complexes (ULC). We hypothesize that the propensity to pathogenicity is determined by two interrelated aspects of antibody biology relating to ULC: 1) Composition ofthe complement determinant regions (CDRs) and 2) Epitope specificity. These features work in concert to permit access of antibody to antigenic epitopes within the complex charge field of PF4/H to foster formation of pathogenic ULCs. We have characterized two isotype matched murine anti-human PF4/H antibodies, KKO, which forms ULC in the presence of heparin or GAGs and causes HIT in an animal model, and RTO which binds less well to PF4 in the presence of heparin and does not cause HIT in vivo. We will systematically convert the CDRs of non- pathogenic RTO to simulate pathogenic KKO using molecular modeling and the crystal structures of their respective Fabs.
In Specific Aim 1, the impact of mutations of epitope specificity will be determined using a panel of existing and novel PF4 mutants and we will examine their capacity to induced oligomerization of PF4 teframers.
In Specific Aim 2, we will use scanning electron microscopy to assess the structure of ULC clusters on the surface of platelets, monocytes and endothelium stabilized by KKO, but not RTO, that we posit incorporate and promote activation of FcyRllas and we will characterize antibody-PF4 interactions in real time using optical trap-based force spectroscopy.
In Specific Aim 3, we will assess the impact of these changes in antibody on activation of an FcyRlla cell line, platelets and cultured endothelial cells in vitro and the induction of thrombocytopenia and thrombosis in vivo. Successful completion of this project will help elucidate the biologic basis of pathogenic autoantibodies, improve diagnosis by developing ELlSAs based on informative mutants and potentially ameliorate disease severity using specific PF4 antagonists.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01HL110860-03
Application #
8695462
Study Section
Heart, Lung, and Blood Program Project Review Committee (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
McKenzie, Steven E; Sachais, Bruce S (2014) Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol 21:380-7
Cines, Douglas B; Lebedeva, Tatiana; Nagaswami, Chandrasekaran et al. (2014) Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 123:1596-603
Yeung, Jennifer; Tourdot, Benjamin E; Fernandez-Perez, Pilar et al. (2014) Platelet 12-LOX is essential for Fc?RIIa-mediated platelet activation. Blood 124:2271-9
Cines, Douglas B; Cuker, Adam; Semple, John W (2014) Pathogenesis of immune thrombocytopenia. Presse Med 43:e49-59
Kowalska, M Anna; Zhao, Guohua; Zhai, Li et al. (2014) Modulation of protein C activation by histones, platelet factor 4, and heparinoids: new insights into activated protein C formation. Arterioscler Thromb Vasc Biol 34:120-6
Litvinov, Rustem I; Yarovoi, Serge V; Rauova, Lubica et al. (2013) Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. J Biol Chem 288:33060-70
Zhi, Huiying; Rauova, Lubica; Hayes, Vincent et al. (2013) Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood 121:1858-67
Lee, Grace M; Arepally, Gowthami M (2013) Diagnosis and management of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 27:541-63
Lee, Grace M; Welsby, Ian J; Phillips-Bute, Barbara et al. (2013) High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood 121:2828-35
Cuker, Adam; Rux, Ann H; Hinds, Jillian L et al. (2013) Novel diagnostic assays for heparin-induced thrombocytopenia. Blood 121:3727-32

Showing the most recent 10 out of 11 publications